Rimegepant (Nurtec ODT) vs Ubrogepant (Ubrelvy)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Migraine

Shared mechanism: CGRP receptor · full Migraine pipeline

Rimegepant (Nurtec ODT)

Marketed by Pfizer and partners

Approved in Migrainesmall molecule
Reliable signal

NCT03235479 · Phase 3 · completed

This was a randomized, triple-masked, placebo-controlled trial with 1,162 randomized participants. Its two primary clinical endpoints were met: 2-hour pain freedom was 19.2% with rimegepant versus 14.2% with placebo (p=0.0298), and freedom from the most bothersome symptom was 36.6% versus 27.7% (p=0.0016).

Next expected readout: November 2026 · NCT06641466 (registry estimate)

Reported efficacy

Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) (met)

Result source: NCT05810038

Ubrogepant (Ubrelvy)

Marketed by AbbVie

Approved in Migrainesmall molecule
Reliable signal

NCT02828020 · Phase 3 · completed

This was a large, randomized, double-blind, placebo-controlled trial with 1,672 participants. Both ubrogepant doses met both primary clinical endpoints, with statistically significant improvements over placebo in pain freedom and relief of the most bothersome migraine-associated symptom at 2 hours.

Next expected readout: May 2027 · NCT05125302 (registry estimate)

Reported efficacy

Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants (met)

Result source: NCT04492020

Results for Migraine

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Rimegepant (Nurtec ODT)
Change From Baseline in the Mean Number of Total Migraine Days Per Month in the Last 4 Weeks of the DBT Phase (OP and Weeks 9 to 12 of the DBT phase): Rimegepant - Randomization Phase -4.3 Total Migraine Days per Month (95% CI -4.83 to -3.87) | Placebo - Randomization Phase -3.5 Total Migraine Days per Month (95% CI -4 to -3.04) NCT03732638 · Phase 2/3 · design grade: moderate · reviewed ClinicalTrials.gov result
Mean Change From the Observation Phase (OP) in Number of Migraine Days Per Month Over the Entire DBT Phase (Weeks 1 to 12) (OP (screening of 4 weeks prior to randomization), DBT phase (Weeks 1 to 12)): DBT Rimegepant -3.64 Migraine days per month (Standard Error 0.14) | DBT Placebo -2.63 Migraine days per month (Standard Error 0.14) NCT05810038 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Mean Change From Baseline in Number of Migraine Days Per Month From Week 9 to 12 of the Double-Blind Treatment (DBT) Phase (Baseline, Week 9 to Week 12 of the DBT phase): Rimegepant -2.4 Days/month (95% CI -2.93 to -1.96) | Placebo -1.4 Days/month (95% CI -1.87 to -0.91) NCT05399485 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result
Ubrogepant (Ubrelvy)
Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose (24 hours after taking double-blind study intervention during the prodrome): Placebo 121 Participants | Ubrogepant 100 mg 190 Participants NCT04492020 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Rimegepant (Nurtec ODT)'s landscape · Ubrogepant (Ubrelvy)'s landscape